USO 24006

A Phase III, Randomized, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig o Rilvegostomig Monotherapy Versus Standard of Care, Kasunod ng Kumpletong Tumor Resection, sa mga Kalahok na May Stage I Adenocarcinoma Non-small Cell ctD na High-positive na Kanser sa Baga o Mataas na Pagkakaroon ng Patatas ng Cell. (TROPION-Lung12) (D926TC00001)

Mga Uri ng Sakit: Pananaliksik sa Kanser sa Baga

Mga Kinakailangan sa Kwalipikasyon:

Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
Complete surgical resection (R0) of the primary NSCLC
Unequivocal no evidence of disease at post-surgical
Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
Adequate bone marrow reserve and organ function

Para sa karagdagang impormasyon sa pagsubok na ito CLICK HERE .

Available sa:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach ( Princess Anne )
• Williamsburg